Jubilant Pharmova has announced a key leadership transition within its finance department. Mr. Arun Kumar Sharma will step down as Chief Financial Officer effective May 22, 2026, moving into an advisory role for the Chairmen. Succeeding him, Mr. Ashish Mukkirwar has been appointed as the new Chief Financial Officer and Key Managerial Personnel, with his tenure officially beginning on May 23, 2026.
Leadership Transition
Jubilant Pharmova has confirmed a significant change in its senior management team. Mr. Arun Kumar Sharma, who has served as the company’s Chief Financial Officer, will relinquish his current responsibilities at the close of business hours on May 22, 2026. Recognizing his contributions, the company has announced that Mr. Sharma will transition to a new role as an Advisor to the Chairmen.
Appointment of New CFO
Following the recommendation of the Nomination, Remuneration and Compensation Committee, the Board of Directors has appointed Mr. Ashish Mukkirwar as the new Chief Financial Officer and Key Managerial Personnel. This appointment is effective from May 23, 2026.
Professional Background of the Incoming CFO
Mr. Mukkirwar joins the organization with over two decades of progressive experience in corporate finance, capital markets, and strategic management. He previously served as the Group Vice President & CFO – Global Formulations Business at Glenmark Pharmaceuticals. His career includes senior leadership roles at major global financial institutions like Moelis & Company and UBS Investment Banking. Mr. Mukkirwar holds an MBA from the Indian Institute of Management, Kolkata, and brings deep expertise in driving financial performance and global strategy.
Auditor Confirmation
In addition to the leadership changes, the company has declared that its Statutory Auditors, M/s Walker Chandiok & Co. LLP, have issued an unmodified opinion on the Audited Financial Results (Standalone and Consolidated) for the financial year ended March 31, 2026.
Source: BSE
